ATE213155T1 - Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis - Google Patents

Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis

Info

Publication number
ATE213155T1
ATE213155T1 AT94914102T AT94914102T ATE213155T1 AT E213155 T1 ATE213155 T1 AT E213155T1 AT 94914102 T AT94914102 T AT 94914102T AT 94914102 T AT94914102 T AT 94914102T AT E213155 T1 ATE213155 T1 AT E213155T1
Authority
AT
Austria
Prior art keywords
polypeptide
leee
factor
preparation
hirudo medicinalis
Prior art date
Application number
AT94914102T
Other languages
English (en)
Inventor
Moshe M Werber
Elisha P Zeelon
Avigdor Levanon
Rachel Guy
Arie Goldlust
Meir Rigbi
Amos Panet
Meir Fischer
Original Assignee
Bio Technology General Corp
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp, Yissum Res Dev Co filed Critical Bio Technology General Corp
Application granted granted Critical
Publication of ATE213155T1 publication Critical patent/ATE213155T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94914102T 1993-04-09 1994-04-08 Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis ATE213155T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4580493A 1993-04-09 1993-04-09
PCT/US1994/003918 WO1994023709A1 (en) 1993-04-09 1994-04-08 Production of recombinant factor xa inhibitor of leech hirudo medicinalis

Publications (1)

Publication Number Publication Date
ATE213155T1 true ATE213155T1 (de) 2002-02-15

Family

ID=21939978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914102T ATE213155T1 (de) 1993-04-09 1994-04-08 Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis

Country Status (8)

Country Link
US (1) US5801017A (de)
EP (1) EP0693925B1 (de)
JP (1) JPH08510903A (de)
AT (1) ATE213155T1 (de)
AU (1) AU6630294A (de)
DE (1) DE69429858D1 (de)
IL (1) IL109258A0 (de)
WO (1) WO1994023709A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ270194A (en) * 1994-01-07 1996-05-28 Ciba Geigy Ag Hirustasin, a serine protease inhibitor from hirudo medicinalis
DE4440892A1 (de) * 1994-11-17 1996-05-23 Gruenenthal Gmbh Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
GB9930659D0 (en) * 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
EP2468869B1 (de) 2007-01-31 2015-03-18 Pfenex Inc. Bakterielle Leader-Sequenzen für erhöhte Expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
US4742004A (en) * 1984-08-27 1988-05-03 Bio-Technology General Corp. Method for producing enzymatically active eucaryotic sod in bacteria
DE3689525D1 (de) * 1985-07-17 1994-02-24 Hoechst Ag Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel.
IL83912A (en) * 1986-09-18 1993-05-13 Pennsylvania Hospital Protein having anticoagulant and antimetastatic properties
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
DE69429858D1 (de) 2002-03-21
EP0693925A1 (de) 1996-01-31
JPH08510903A (ja) 1996-11-19
IL109258A0 (en) 1994-07-31
EP0693925B1 (de) 2002-02-13
EP0693925A4 (de) 1998-08-26
AU6630294A (en) 1994-11-08
US5801017A (en) 1998-09-01
WO1994023709A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
DK0423302T3 (da) Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
ATE317398T1 (de) Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert
ES8306797A1 (es) Un metodo para producir un polipeptido.
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
GR3024752T3 (en) Pea protein hydrolyzate, method for production thereof and use thereof
RO91186B (ro) Procedeu pentru prepararea unor peptide cu actiune asupra functiei glandei pituitare
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
GB8914122D0 (en) Polypeptide expression
BR9802403A (pt) Proteìna tendo atividade transglutaminase, dna, transformante, e, processo para produzir uma proteìna tendo uma atividade transglutaminase.
ATE146219T1 (de) Polypeptid
KR920016464A (ko) 재조합 단백질의 개선된 활성화 방법
BR0012265A (pt) Fator estimulante de colÈnia de granulócitos humano modificado e processo para produzir o mesmo
ATE213155T1 (de) Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis
AU7873798A (en) N-terminally extended proteins expressed in yeast
DE69328992D1 (de) Mutanten von menschlichem Antithrombin III
KR850001287A (ko) 폴리펩타이드의 제조방법
DE69500108D1 (de) Stabile D-N-alpha-Carbamylase Mutanten
AU5610194A (en) Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
AU2003287267A1 (en) Lutzomyia longipalpis polypeptides and methods of use
YU200091A (sh) Delecioni mutanti ahasarezistentni na herbicide
KR850001286A (ko) 개량 플라스미드 벡타의 제조방법
EP0750040A3 (de) Varianten des Makrophagen-stimulierendes-Proteins und Verfahren zur ihrer Herstellung
EP0232845A3 (de) Induzierbare Wärmeschock- und Amplifizierungssysteme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties